As COVID-19 spreads across the globe, new research funding opportunities are cropping up, along with questions regarding how COVID-19-related disruptions to research might affect current federal funding. Answers to many of those questions and information on a variety of new funding opportunities is provided by clicking on the related link below:

1. New Covid-19 research funding opportunities
2. COVID-19 related research news and policy updates
3. Guidance for federally-funded clinical trials and human subjects studies affected by COVID-19
4. Free access and free services for researchers related to COVID-19
5. COVID-19 news by Chan faculty

1. COVID-19 research funding opportunities

Internal COVID-19 Funding Announcements

Non-federal COVID-19 Funding Announcements

*NEW: American Heart Association: Rapid Response Grant and its Cardiovascular Impact
Deadline: April 06, 2021
This grant invites cardiovascular-focused applications that will contribute to understanding the cardiovascular and cerebrovascular pathogenesis, diagnosis, prevention, clinical manifestations, clinical management (including critical care management) and social behaviors which can lead to dissemination, containment, and complications of COVID-19. Because of the urgency of this issue, innovative, highly impactful short-term proposals (9-12 months), which can show progress within the period of this award, are sought.

*NEW: Patient Centered Outcomes Research Institute: COVID-19 PFA
Deadline: May 26, 2020
This PFA supports innovative, high-impact studies that fit clearly within PCORI’s core mission of patient-engaged and patient-centered comparative clinical effectiveness research. The objectives are to (1) strengthen the understanding of different approaches to mitigate the impact of COVID-19 on individuals, communities, healthcare providers, and healthcare systems; and (2) provide evidence to inform clinical and public health responses, decision making, and planning. PCORI will encourage the use of diverse methods, including interventional studies and the use of natural experiments, to conduct research on an accelerated timeline.
*NEW: Robert Wood Johnson: Pioneering Ideas: Exploring the Future to Build a Culture of Health
Deadline: Continuous
This award seeks ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, we welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health. While this call for proposals is focused on broader and longer-term societal trends and shifts that were evolving prior to the COVID-19 outbreak, we recognize the unique circumstances and learning created by the COVID-19 pandemic may inform your response. It is at your discretion whether you propose a project related to the pandemic directly or indirectly.

*NEW: American Lung Association: COVID-19 and Emerging Respiratory Viruses Research Award
Deadline: May 30, 2020
This award supports applications that address the following types of clinical, basic, translational, and population health questions: A new understanding of the basic biology of respiratory viruses that could lead to better treatment and prevention; Development of novel therapeutics and vaccines; Understanding host factors that alter response to these infections; Understanding individual, regional, or social factors increasing or decreasing community spread of COVID-19 and other respiratory viruses; and Case tracking and epidemiological approaches to understanding COVID-19 and other respiratory viruses.

*NEW: The Microsoft Corporation: AI for Health Grant
Deadline: June 15, 2020
This award invites proposals for its artificial intelligence for health COVID-19 grant, which supports research with potential benefits and a defined impact to the COVID-19 response. *The grant provides Azure cloud and high-performance computing capabilities.

Deadline: May 11, 2020
This grant invites applications for research on women, victimization and domestic violence, with a particular emphasis on the impact of the current COVID-19 pandemic. Projects may focus on developing or developed countries.

AXA Research Fund: Exceptional Flash Call for Proposals
Deadline: May 7, 2020
Mitigating risk in the wake of the COVID-19 pandemic, will support research projects in the following areas: protecting vulnerable populations from epidemics and catastrophes, including COVID-19; improving data collection and quality in health; understanding the effects of confinement and social distancing; early warning and preparedness; and preserving the environment and our health. Preference will be given to projects with a local focus and potential applicability on a global scale. Academic institutions globally are eligible to apply. The grants aim at supporting mid-career researchers.

American Lung Association: Emerging Respiratory Viruses Research Award
Deadline: May 30, 2020
This award seeks proposals to advance research against emerging respiratory pathogens like SARS-CoV-2. All research must directly be related to COVID-19 or other viral respiratory threats that may arise in the future.
American College of Emergency Physicians (ACEP)/Emergency Medicine Foundation (EMF): COVID 19 Research Grant  
Deadline: June 5, 2020  
This grant supports research that will provide high-impact new knowledge to advance emergency patient care, improve response of hospitals, healthcare and emergency medical services systems, and protect emergency medicine healthcare professionals during pandemics.

Private Enterprise Development in Low-Income Countries: Special Exploratory Research Grant Call on the Economic Impacts of Coronavirus  
Deadline: June 1, 2020  
Private Enterprise Development in Low-Income Countries (PEDL) is inviting applications to a special Exploratory Research Grant call for projects addressing the economic impacts of coronavirus in developing countries. Funding of £10,000 to £40,000 will be provided to individual researchers for research that can inform policymakers and other stakeholders on the economic impacts of coronavirus in developing countries so that the costs can be mitigated as much as possible.

Amgen Foundation: COVID-19 Relief Support  
Deadline: none  
The Amgen Foundation is dedicated to combating this pandemic by working across several fronts to apply their unique strengths in genetics, immunology, and antibody engineering to prevent and treat COVID-19. The Foundation’s COVID-19 Relief Support program is dedicated to supporting patients and communities in the fight against COVID-19. Support is provided in the U.S., including Puerto Rico.

Autism Science Foundation/ COVID-19 Pivot Grant  
Deadline: May 10, 2020  
This grant is intended to help researchers manage changes in research projects due to the COVID-19 emergency. The funding will not fully support a project, but rather is meant to help support new costs encountered due to adaptations or modifications to an original research plan as a result of the current shutdown across research institutions.

Merck KGaA: Research Grant for Pandemic Preparedness  
Deadline: Rolling  
This grant seeks proposals that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections.

Coalition for Epidemic Preparedness Innovation: Call for Proposals  
Deadline: May 10, 2020  
CEPI is looking for partner organizations with which to establish centralized laboratory assays of immune responses to the many COVID-19 vaccine candidates so that data on these vaccines can be meaningfully compared to determine their efficacy.

The United States–India Science & Technology Endowment Fund: Covid 19 Ignition Grants  
Deadline: May 15, 2020  
This fund supports joint entrepreneurial initiatives addressing the development and implementation of new technologies, tools, and systems to address COVID-19 related challenges including monitoring, diagnosis, health and safety, public outreach, information and communication.

Pfizer: COVID-19: Continuity in Care for Patients with Metastatic Breast Cancer Grant Support Program
Deadline: May 21, 2020
This RFP provides support to nursing associations, cancer centers, hospitals or healthcare systems so that they may improve their systems-of-care for patients with metastatic breast cancer who receive oral cancer medicines during the COVID-19 pandemic.

Patient-Centered Outcomes Research Institute: enhancements to existing Research Projects and Engagement Awards
Deadline: Rolling
PCORI is requesting enhancements to existing Research Projects and Engagement Awards that can be initiated quickly to influence the outcome of the current pandemic and that have some relationship to the original award, using existing teams that are currently funded: COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects; COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards

Fast Grants: Fast Funding for COVID-19 Science
Deadline: Not announced
These grants are for scientists at an academic institution currently working on a COVID-19 related project and in need of funding. Fast Grants are $10k to $500k and decisions are made in under 48 hours.

Harrington Scholar Award for Coronavirus: Advancing Therapies for Treating Coronavirus and Future Deadly Viruses
Deadline: April 30, 2020
This award provides funding and expert guidance and oversight in all aspects of drug/therapeutics development, while taking no rights to intellectual property, which is retained by the award recipient and their institution.

Pfizer: COVID-19 Independent Medical Education Grants
Deadline: May 22, 2020
Pfizer supports educational programs for healthcare providers focused on the recognition, diagnosis, treatment, and overall care management of patients with COVID-19, especially programs that include tools designed to help HCP’s educate patients and caregivers on the disease state, preventative measures, and emerging strategies for COVID-19 treatment.

Pfizer: Quality & Process Improvement Grants
Deadline: May 22, 2020
The grant provides support to hospitals or healthcare systems so that they may evaluate and improve their systems-of-care for COVID-19 patients. Funds can be used for staff training or clinical process improvement. While hospitals are dealing with the urgent care of patients with COVID-19, these grants can be used to address procedural challenges and needs. Quality improvement grants can also be used to help facilitate the sharing and exchange of best practices across hospital systems or geographic regions. Our goal is that the quality or process of care of patients will be improved with this additional funding support.

Russel Sage Foundation: COVID-19 Research Grants
Deadline: May 21, 2020
The foundation funds research that analyzes social, political, economic, or psychological disruptions resulting from the coronavirus crisis that affect social and living conditions in the United States. All LOIs must focus on issues related to the foundation’s core program areas and special initiatives: Behavioral
Mozzila: COVID-19 Solutions Fund  
Deadline: Rolling  
The fund will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related).

California Institute for Regenerative Medicine (CIRM)  
Deadline: Open on a bi-monthly basis.  
The CIRM has allocated $5 million in funding for peer-reviewed regenerative medicine and stem cell research that could quickly advance treatments for COVID-19. Support is provided for promising discovery, preclinical, and clinical trial stage projects.

IBM: Call for Code Global Challenge  
Deadline: July 31, 2020  
The Call for Code Global Challenge, an initiative of IBM, asks the world's developers to build solutions for COVID-19 and climate change. Interests include crisis communication, remote education, and community cooperation.

Nellie Mae Education Foundation: Racism is a Virus Too  
Deadline: Rolling basis until resources are exhausted  
The Nellie Mae Education Foundation created a rapid response fund to respond to the hate crimes and bias against Asian American communities in New England resulting from COVID-19.

Omidyar Network India: Rapid Response Funding for COVID-19  
Deadline: Not announced  
The Omidyar Network India has announced a rapid response window to fund proposals that support the lower 60% of India’s income distribution in managing and mitigating the challenges that come with Covid-19. Support is provided for initiatives that strengthen containment, detection and treatment, support crisis management capabilities, and enhance resilience and recovery in the wake of Covid-19.

Open Road Alliance  
Deadline: Not announced  
The Open Road Alliance is offering charitable grants to organizations responding directly to COVID-19, with priority given to organizations and activities that have a clear and direct role in ‘flattening the curve’ and thus limiting, shortening, or minimizing the economic and social, as well as health effects of the pandemic. Loans are also available to organizations affected by COVID-19, including those with lost event revenue, those delivering vital community services, and social enterprises.

Innovative Medicines Initiative  
This Initiative is a jointly funded partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations. The initiative seeks to involve a broader range of partners, including mid-sized companies, from different sectors e.g. biomedical imaging, medical information technology, diagnostic and/or animal health industries.
Amazon Web Services (AWS): Diagnostic Development Initiative  
Deadline: June 30, 2020  
This Initiative provides support for innovation in rapid and accurate patient testing for 2019 novel coronavirus (COVID-19), and other diagnostic solutions to mitigate future outbreaks.

Novartis: COVID-19 Response Fund  
Deadline: Not announced  
These grants will support public health initiatives designed to help communities manage challenges posed by the pandemic focused on but not limited to the following areas: 1. Strengthening local and national healthcare infrastructure including funding of additional medical personnel, sourcing of medicines and medical equipment; 2. Establishing digital platforms for COVID-19 related data collection, remote delivery of healthcare and effective dissemination of important public health information; and 3. Creating new or enhancing new community health programs specific to the pandemic response.

Enhancing Learning and Research for Humanitarian Assistance: Research for Health in Humanitarian Crises (R2HC) Programme  
Deadline: July 16, 2020  
This program aims to improve health outcomes by strengthening the evidence base for public health interventions in humanitarian crises.

Medical CBRN Defense Consortium: CoV Pandemic Response  
Deadline: Submissions will be accepted through May 31.  
This RFI seeks white papers in response to the novel Coronavirus (2019-nCoV) pandemic in the United States in the following areas: diagnostics/monitoring; surveillance; information systems and technology; therapeutics (drugs and/or drug/device combinations, or platforms currently under development); prophylactics; and clinical trials.

Bill & Melinda Gates Foundation, Wellcome and Mastercard: COVID-19 Therapeutics Accelerator  
Deadline: varies  
This initiative speeds development and access to therapies for COVID-19 by coordinate R&D efforts and removing barriers to drug development and scale-up to address the epidemic.

The American Heart Association: Rapid Response Grant COVID-19 and Its Cardiovascular Impact  
The AHA invites cardiovascular-focused applications that will contribute to understanding the cardiovascular and cerebrovascular pathogenesis, diagnosis, prevention, clinical manifestations, clinical management (including critical care management) and social behaviors which can lead to dissemination, containment, and complications of COVID-19.

Massachusetts Institute of Technology Solve: Health Security and Pandemics Challenge  
Deadline: June 18, 2020  
MIT Solve is seeking tech innovations that can slow and track the spread of an emerging outbreak, for example by improving individual hygiene, developing low-cost rapid diagnostics, analyzing data that informs decision making, and providing tools that support and protect health workers.
Massachusetts Institute of Technology Solve: The Elevate Prize for Health Security
The Elevate Prize for Health Security will be awarded to one Solver team from the Health Security & Pandemics Challenge. This prize is supported by The Elevate Prize Foundation, which recognizes that there are heroes all over the world who are putting their health and safety at risk to treat those who are infected and to save lives. Now more than ever, it is critical to recognize and uplift those who are elevating humanity. The Solver team that is selected will be named an Elevate Prize Global Hero and will participate in both the MIT Solver program and the Elevate Prize Global Heroes program, receiving a minimum of $300,000 over two years and ongoing support from The Elevate Prize Foundation and MIT Solve.

Federal COVID-19 Funding Announcements

*NEW: Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System (NOT-NS-20-051)
Deadline: May 1, 2020-April 15, 2021
NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

*NEW: HHS: Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed) (PAR-20-177)
Deadline: April 30, 2021
This opportunity provides an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

*NEW: Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed) (PAR-20-178)
Deadline: Rolling
This opportunity provides an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

*NEW: Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis (NOT-CA-20-054)
Deadline: Not announced
The COVID-19 pandemic is a global health crisis that has engaged the attention of researchers who want to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients’ disease progression, response to therapy, care delivery, or survivorship.
*NEW: Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials
Deadline: October 6, 2020
NHLBI seeks to leverage existing clinical trials expertise and, using NHLBI programs that are actively conducting Phase I-III clinical trials, to rapidly initiate and conduct Phase I-Phase I/II (bridging) clinical trials in patients at risk for SARS-CoV-2 infection and/or patients with COVID-19. It is strongly recommended that the parent activity code be one of the following: P01, R01, R33, R41, R42, R43, R44, U01, U24, U54, UH3, or UM1. Topics of specific interest to the NHLBI include the safety and efficacy of interventions for primary prevention and/or treatment of COVID-19, associated clinical phenotypes, and surrogate outcomes, relevant to heart, lung, and blood (HLB) diseases.

*NEW: NOSI: Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
Deadline: June 19, 2020
OSC seeks new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. Topics: Any relevant area of innovative research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics.

*NEW: NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System
Deadline: April 14, 2021
This NOSI highlights the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS's scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

*NEW: UK Ministry of Defense/Defense and Security Accelerator: Point of Care Diagnostics at the Front Line
Deadline: September 26, 2020
This call supports diagnostics technologies that provide information to enable clinicians to earlier diagnose and ultimately treat individuals exposed to chemical and biological hazards. Proposals should address technologies that would enable the diagnosis of individuals exposed to a wide variety of agents, regardless of starting technology readiness level, up to TRL 6. These technologies can be targeted at the agents themselves or at host biomarkers that change as a result of exposure.

*NEW: UK Ministry of Defense/Defense and Security Accelerator: COVID Fast Track
Deadline: May 12, 2020
This call seeks ideas or novel approaches that could boost the ministry's capabilities in support of the national effort against coronavirus. Proposals should be clear as to whether they seek to address the current covid-19 threat or future similar scenarios. Proposals addressing the current pandemic must have the ability or relevant permissions to successfully deliver the project despite current working restrictions. Proposals for products or services that are already available on the market to solve challenges related to the coronavirus pandemic will not be considered. Proposals must address the development of novel and innovative solutions.
*NEW: National Institute of Biomedical Imaging and Bioengineering (NIBIB): Rapid Acceleration of Diagnostics (RADx)
Deadline: Rolling
This call supports novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. **Topics:** SARS-CoV-2 diagnostic testing technologies in two stages: Early stage: transformative innovations based on novel testing strategies that have potential for major scale up; Advanced stage: modification and optimization of existing SARS-CoV-2 testing approaches, including clinical laboratory tests, that can dramatically increase testing capacity.

National Institute of Food and Agriculture (NIFA)
Deadline: June 4, 2020
This program addresses the need to develop and deploy rapid, reliable, and readily adoptable strategies across the food and agriculture enterprise in response to the COVID-19 pandemic.

HHS: Health Resources and Services Administration Rural Tribal COVID-19 Response Program
Deadline: May 6, 2020
The purpose is to provide maximum flexibility to assist tribes, tribal organizations, urban Indian health organizations, and health service providers to tribes to prevent, prepare for, and respond to the coronavirus and the evolving needs in rural communities.

EPA: Removal Emergency Response Program
Deadline: June 10, 2020
This notice announces the availability of funds and solicits applications from eligible entities to promote the participation of individual State and territorial programs in research activities with the mission of advocating for and supporting State emergency response readiness and removal program planning and preparedness.

Deadline: May 04, 2020 (first available)
NCATS is soliciting applications for Administrative Supplements (through PA-18-591) and Emergency Competitive Revisions (through PA-20-135) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients.

Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
Deadline: varies
NIA is encouraging the submission of applications for either Administrative Supplements (PA-18-591) or Competitive Revisions (PA-18-935) to active grants to address the following research areas of interest: **Division of Aging Biology** (DAB) Research Interests; **Division of Neuroscience** (DN) Research Interests; **Division of Geriatrics and Clinical Gerontology** (DGCG) Research Interests; **Division of Behavioral and Social Research** (DBSR) Research Interests.

Notice of Eligibility Change for NIDCD Urgent Competitive Revisions and Administrative Supplements for Research on COVID-19
Deadline: n/a
This NOSI revises the language regarding the activity codes of currently funded NIDCD grants that are eligible to apply to NOT-DC-20-004, Notice of Special Interest (NOSI) regarding the Availability of Urgent
Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19). Current Language: Only R01 and U01 activity codes of currently funded NIDCD grants are eligible to apply to this NOSI. The funding instrument, or activity code, will be the same as the parent grant; Revised Language: Only R01, U01, R42, and R44 activity codes of currently funded NIDCD grants are eligible to apply to this NOSI. The funding instrument, or activity code, will be the same as the parent grant.

**NIH Supplemental Support for Donated PPE and Supplies**
Have you donated personal protective equipment, lab equipment, lab supplies, or travel costs to support COVID-patient care, etc.? If so, NIH funding ICs will consider administrative supplements to support existing resources that were diverted due to COVID-19. Please contact your NIH funding IC for specific details regarding supplemental support.

**Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA**
Deadline: May 15, 2020 (first available)
This NOSI encourages applications to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes.

**Notice of Special Interest regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for the Establishment and Maintenance of a Research Database for Neurological Manifestations of the SARS-CoV-2**
Deadline: May 9, 2020
NINDS is interested in developing systems to collect data on the neurologic effects of COVID-19 infection in patients requiring intensive care and less severely affected individuals seen by health care practitioners.

Deadline: June 01, 2020 (first upcoming)
For research on how coinfection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent for Coronavirus Disease 2019 (COVID-19), might affect HIV-associated comorbidities, coinfections, and complications (CCCs) within its mission.

**Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities (NOT-MD-20-019)**
Deadline: Rolling - May 01, 2020-May 2, 2021
The National Institute on Minority Health and Health Disparities seeks research on the impact of the novel Coronavirus (SARS-CoV-2) pandemic causing COVID-19 disease outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations.

**Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus (NOT-TR-20-017)**
Deadline: Rolling - May 15, 2020- January 26, 2022
For research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus (NOT-TR-20-016)
For research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus (NOT-MH-20-047)
Deadline: Rolling - March 27, 2020-April 16, 2021
For research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH.

Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-CA-20-043)
Deadline: Rolling - April 14, 2020-June 26, 2020
This NOSI encourage applications from small businesses with NCI-funded active NCI SBIR/STTR awards that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19) in cancer patients, cancer survivors, and in the general population.

Deadline: Rolling - May 01, 2020-May 04, 2021
For research to understand the impact of environmental exposures on (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus. NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-DK-20-018)
Deadline: June 01, 2020 (first upcoming)
NIDDK is particularly interested in projects focusing on the direct action of the virus on kidney, gastrointestinal tract function, and the endocrine/metabolic system, and the collection of biosamples that will inform the understanding of renal, gastrointestinal, and endocrine/metabolic sequelae of viral infection. Pilot clinical studies (observational and interventional) that support the understanding or treatment of COVID-19-related diseases within the mission of the NIDDK are also of interest.

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) (NOT-DC-20-004)
Deadline: Rolling from April 07, 2020 to June 02, 2020
For research on SARS-CoV-2 and COVID-19 in relation to NIDCD’s scientific mission areas of hearing, balance, taste, smell, voice, speech and language.

BARDA’s Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement
Deadline: June 30, 2020
BAA seeks abstract submissions for the following: Diagnostic assays, screening and model development, vaccines, advanced manufacturing.

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) (NOT-AI-20-030)
Deadline: varies
NIAID and NIGMS are offering Competitive Revisions to active grants addressing research objectives focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV. NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens.

Notice of Special Interest: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed) (NOT-ES-20-014)
Deadline: varies
NIEHS WTP grantees are re-programming existing extramural funds to provide Coronavirus preparedness training to their worker populations. The newly proposed training under this announcement would be utilized to award supplemental funding to expand these ongoing Coronavirus response training efforts.

Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) (NOT-TR-20-012)
Deadline: June 05, 2020-October 17, 2020
National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. NCATS is soliciting applications to PAR-17-465, PAR-18-462, and PAR-18-332.

Deadline: June 2020.
The Agency for Healthcare Research and Quality intends to publish a new funding opportunity announcement using the R01 mechanism to support novel, high-impact studies evaluating health system and healthcare professional responsiveness to COVID-19. This Notice is being provided to allow potential applicants sufficient time to develop responsive applications.

Notice of Intent: Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Address Health System Responsiveness to COVID-19
Deadline: mid-May
Agency for Healthcare Research and Quality intends to publish a new funding notice allowing requests for urgent revision supplements to existing AHRQ grants and cooperative agreements to address health
system responsiveness to COVID-19. AHRQ intends to allow grantees with active AHRQ research grants to submit requests for competitive revision supplements to address timely health system and healthcare professional response to COVID-19.

**Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-HG-20-030)**

Deadline: varies
This NOSI encourages the submission of applications for Competitive Revisions to support genomic research on SARS-CoV-2 and COVID-19 disease. Of particular interest are genomic studies utilizing generalized approaches that take advantage of human research or model systems to study the consequences of SARS-CoV-2 infection. Supported research is expected to guide and inform future efforts to diagnose, prevent, mitigate, or treat this viral infection.

**Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)**

Deadline: varies
NIA is encouraging the submission of applications for either Administrative Supplements (PA-18-591) or Competitive Revisions (PA-18-935) to active grants to address the following NIA division research interests: Aging Biology; Neuroscience; Geriatrics and Clinical Gerontology; and Behavioral and Social Research.

**HHS: Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)**

Deadline: June 16, 2020
The U34 award will support clinical trial planning. This includes collection of feasibility data and complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use. The clinical trial that is being planned must aim to repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase I trial for a different indication by the time a clinical trial planning award is made. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair.

**DoD: Newton Award for Transformative Ideas during the COVID-19 Pandemic**

Deadline: May 15, 2020
This award will be presented to a single investigator or team of up to two investigators that develops a “transformative idea” to resolve challenges, advance frontiers, and set new paradigms in areas of immense potential benefit to DoD and the nation at large. Proposals should aim to produce novel conceptual frameworks or theory-based approaches that present disruptive ways of thinking about fundamental scientific problems that have evaded resolution, propose new, paradigm-shifting scientific directions, and/or address fundamental and important questions that are argued to be undervalued by the scientific community. Approaches can include analytical reasoning, calculations, simulations, and thought experiments. While data collection and production are therefore allowed, all supporting data should be generated without the use of laboratory-based experimentation or instrumentation.


Deadline: varies
This NOSI highlights the urgent need for research on the 2019 novel Coronavirus, particularly in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to
facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. NCATS is soliciting applications for Administrative Supplements to UL1, U01, and R21 awards (through PA-18-591), Collaborative Innovation Awards to U01 and R21 awards (through PAR-19-099 and PAR-19-100, respectively), and Competitive Revisions for UL1 awards for each of the non-administrative supplement awards (through PAR-19-337).

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)
Deadline: varies
There is an urgent public health need to better understand SARS-CoV-2, particularly to improve the predictive quality of existing models of spread, diagnostics for measurement of transmission, susceptibility and recovery, and development of therapeutic interventions. NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:

- Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).
- Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).
- Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only)

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19) (NOT-DA-20-047)
Deadline: varies
NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Applications in response to this NOSI must be submitted using the following targeted funding opportunity: PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional); and PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).

Notice of Special Interest (NOSI) Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need (NOT-R-20-111)
Deadline: varies
National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. NCATS is soliciting applications for Administrative Supplements to UL1, U01, and R21 awards (through PA-18-591), Collaborative Innovation Awards to U01 and R21 awards (through PAR-19-099 and PAR-19-100, respectively), and Competitive Revisions for UL1 awards for each of the non-administrative supplement awards (through PAR-19-337).

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)
NIGMS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19).

**HHS: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional)**
**Deadline: September 25, 2020**
This FOA solicits competitive revision applications to support the demonstration, and/or dissemination, and/or implementation of highly innovative and impactful translational science projects that address the goals of the CTSA Program that are beyond the original scope of the approved project. Projects will be considered for an increase in support for an expansion of the parent project’s approved scope.

**HHS: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)**
**Deadline: July 11, 2019**
This opportunity supports investigators from three or more CTSA Program hub institutions to either: 1) form new collaborations, or to 2) significantly expand the scientific scope of existing collaborations, or to 3) engage new collaborators in pre-existing collaborations to solve a translational science problem no one hub can solve alone, or disseminate a solution to a translational science problem developed at one hub to other hubs, in so doing testing its robustness to different hub environments and structures and adapting it for further dissemination within outside the CTSA Program consortium if appropriate.

**HHS: Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)**
**Deadline: June 20, 2020**
This opportunity solicits research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens.

**NIH - NIAID and NIGMS: Notice of Special Interest regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus**
**Deadline: Applications accepted on a rolling basis from February 6, 2020 through February 6, 2021**
NIAID and NIGMS highlight the urgent need for research on the 2019 novel Coronavirus: NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV; and NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens.

**NIH – NHLBI: Notice of Special Interest: Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019**
**Deadline: October 6, 2020**
NHLBI is issuing this Notice of Special Interest to highlight the urgent need for research on Coronavirus Disease 2019 and on biological effects of its causative agent, the severe acute respiratory syndrome. Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

**NIH: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)**
**Deadline: varies**
NIH is taking several approaches to support new research in response to severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019. If you are a grantee currently supported by active NIH funding, you may be eligible to apply for an administrative supplement to support SARS-CoV-2/COVID-2019 research.

NIH: Urgent Award Mechanism, Competitive Revisions to Existing NIH Grants
Deadline: varies
The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.

NIH – NIDA: Notice of Special Interest regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Deadline: Applications will be accepted on a rolling basis through March 31, 2021
NIDA is issuing this notice to highlight the urgent need for research on the 2019 Novel Coronavirus. NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

NSF: Dear Colleague Letter 20-052 re Corona Virus Proposals
Deadline: Varies
NSF is accepting proposals to model, track, inform, educate, and prevent the spread of Coronavirus through its existing funding opportunities. NSF invites researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Visit NSF, Dear Colleague 20-053 for Coronavirus proposal FAQs and conditions and process for proposal deadline extension.

NSF-Office of Advanced Cyberinfrastructure (OAC), Dear Colleague Letter 20-055
Deadline: varies
OAC is inviting Rapid Response Research (RAPID) funding mechanism proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

HHS: Development of Medical Products for Novel Coronavirus: Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
Deadline: October 31, 2020
This amendment solicits proposals for advanced development and licensure of COVID-19 diagnostics, vaccines, or medicines such as therapeutics or antivirals.

HHS/CDC: Prototype Development to Combat Novel Coronavirus Disease COVID-19
Deadline: April 30, 2020
The Government seeks to rapidly accelerate the inquiry, testing, and fielding of new 21st century capabilities, employing novel technologies and approaches to the detection of exposure, prevention, containment and treatment of COVID-19 and future emerging threats.

**DOE: Invitation for COVID-19 Scientific Questions (DOE Resources)**
Deadline: Ongoing
The Department encourages scientific questions that underpin COVID-19 response and that the research community may answer using DOE user facilities, computational resources, and enabling infrastructure. Please send research questions that the scientific community may address with DOE resources by email to SC.DCL@science.doe.gov.

### 2. COVID-19 related research news and policy updates

A few of the provisions in the third COVID-19 relief/response package that might be of particular interest to researchers is below. To read more, please download a section-by-section summary and the legislative text.

- **NIST** - $6 million to provide continuity of operations and to conduct research and measurement science to support the testing and treatment of coronavirus. Page 622 of the legislative text.
- **NSF** - $75 million to support research at molecular, cellular, physiological and ecological levels to better understand coronavirus genetics, modes of action, transmission, virulence, and population dynamics. It is expected that many of these funds will be available through the Rapid Response Research funding mechanism. Read Dear Colleague Letter here. Page 629.
- **DOE Office of Science** - $99.5 million for costs related to equipment, personnel, and operations to support research on the coronavirus, including support to provide access to user facilities. Page 654.
- **EPA S&T** - $1.5 million to support research efforts regarding coronavirus – and specifically, research on methods to reduce risks from environmental transmission via contaminated surfaces. Page 713.
- **CDC** - $4.3 billion to support federal, state, and local public health agencies to prevent, prepare for and respond to the coronavirus. Included in that amount is $500 million for global disease detection and emergency response, $500 million for public health data surveillance and analytics infrastructure modernization, and $300 million for the Infectious Diseases Rapid Response Reserve Fund, which supports immediate response activities during outbreaks. Page 728.
- **NIH** - The bill includes $945 million to support research and expand on prior research plans, including developing an improved understanding of the prevalence of COVID-19, its transmission and the natural history of infection, and novel approaches to diagnosing the disease and past infection, and developing countermeasures for the prevention and treatment of its various stages. Of this total, $103 million is allocated for NHLBI, $706 million NIAID, $60 million NIBIB, $36 million NCATS, $30 million OD, and $10 million for National Library of Medicine. When combined with the first supplemental, Congress has provided $1.78 billion for NIH research on COVID-19. Page 730.
- **BARDA** (Biomedical Advanced Research and Development Authority) - At least $3.5 billion to advance construction, manufacturing, and purchase of vaccines and therapeutics to the American people.
- **NASA** - $60 million to support NASA with resources for operational adjustments associated with mission delays caused by NASA center closures related to coronavirus. Page 628. Also, the package includes a number of health-related authorizations, including the HRSA health professionals and nursing workforce development programs.

### 3. Guidance for federally-funded clinical trials and human subjects studies affected by COVID-19
NIH

- Considerations for New and Ongoing Human Subjects Research During the COVID-19 Public Health Emergency under Human Subjects
- Coronavirus Update: Guidance for Peer Reviewers
- OHRP Guidance on COVID-19 under Human Subjects and Clinical Trials
- NHLBI Announces Availability of Frequently Asked Questions (FAQs) for NOT-HL-20-757, Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-HL-20-759)
- notice on Guidance for Cost-Related Flexibilities Available to Support of Competitive Research (SCORE) Award Recipients Affected by COVID-19
- Virtual NIH Activities for Trainees Outside the NIH
- Animal Welfare: COVID-19 Pandemic Contingency Planning for Animal Care and Use Programs
- Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding. The page now includes a link to page update history so you can easily see what’s new.
- New guidance of flexibilities for awardee, students and conference funding during COVID-19 period
- FAQs including new section on Training, Fellowship and Career Development Awards
- An FAQ to address questions regarding proposal submission and award management
- A lenient late-application policy for those who are unable to meet application deadlines due to the COVID-19 emergency
- NIH grant recipients may extend the final budget period of the approved project on active grants one time for up to 12 months without requesting prior approval from NIH

Other Federal Guidance

- USAMRAA’s Supplemental Guidance on Administrative Flexibilities for Grants and Cooperative Agreements in Response to COVID-19 Pandemic
- Frequently Asked Questions (FAQs) published by The Department of Defense (DoD)

4. Free access and free services for researchers related to COVID-19

- NIH VideoCast is a free National Library of Medicine webinar for researchers to learn how to share, discover, and cite COVID-19 data and code in generalist repositories.
- NIH Resource to Analyze (COVID-19) Literature: The COVID Portfolio Tool
  NIH Office of Portfolio Analysis (OPA) has built a comprehensive listing of (COVID-19) publications, available to the public. The portfolio is updated daily and draws from PubMed resources for citations and abstracts of published biomedical literature.
- The COVID-19 High Performance Computing (HPC) Consortium is a unique private-public effort spearheaded by the White House Office of Science and Technology Policy, the U.S. Department of Energy and IBM to bring together federal government, industry, and academic leaders who are volunteering free compute time and resources on their world-class machines.
- COVID-19 Collaboration Platform: This platform is a home for RCT protocols that are available for collaboration.
- CD2H COVID Case Report Forms and Phenotyping Standards website
- The Center for Leading Innovation and Collaboration COVID-19 page
The American Heart Association is working to ensure optimal care for patients with cardiovascular disease who contract coronavirus (COVID-19). Patients with underlying cardiovascular diseases appear to have an increased risk for adverse outcomes with COVID-19. Here are helpful resources for health systems, clinics, care providers, patients and the public.

- **National Library of Medicine**, through its GenBank® sequence database, is providing the biomedical community free and easy access to genome sequences from the novel coronavirus associated with the recent outbreak of pneumonia in Wuhan, China. The outbreak was declared a global health emergency on January 30, 2020 and GenBank® continues to rapidly release data associated with this outbreak as it comes in and welcomes sequence data submissions as well.

- **Internal**: FAS Research Computing has offered to provide enhanced support to Harvard Chan School research related to COVID-19. Examples of support include help with workflow automation to improve efficiency for COVID-19 data analysis, and prioritized assistance for virtual machine requests for hosting a COVID-19 analytic tools website. For more information, please contact the FASRC team via email or attend one of their virtual office hours which are held weekly on Wednesdays from 12 PM to 3 PM.

- **Open Research Dataset** (CORD-19) is a resource of over 45,000 scholarly articles, including over 33,000 with full text, about COVID-19, SARS-CoV-2, and related coronaviruses.

- **IBM has resources to share** — like supercomputing power, virus tracking and an AI assistant to answer citizens’ questions.

- **LitCovid** is a curated literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus.

- The National Institute of Allergy and Infectious Diseases (NIAID) has made 2019 SARS-CoV-2 and other Coronavirus strains and reagents available through its BEI Resources Repository.

- **The American Journal Experts** are offering free language editing and translation services for articles related to coronavirus disease 2019

- Sharing research data and findings relevant to the novel coronavirus (COVID-19) outbreak, with NIH as a signatory to the statement Wellcome Trust news, January 31, 2020

- The BMJ: Coronavirus

- Chongqing VIP Information, a Chinese journal database

- Elsevier: Novel coronavirus information center

- The Lancet: COVID-19 resource centre

- *New England Journal of Medicine*: free Journal content on coronavirus

- Royal Society of Tropical Medicine and Hygiene: Coronavirus free collection


- Wiley Online Library: COVID-19 resources and news

- WHO: COVID-19 Course Series - free online courses from OpenWHO

5. **COVID-19 news by Chan faculty**

- Find the latest COVID news by Chan faculty here.